With the advent of genome editing technology, scientists can now directly target and alter a living organism's genomic sequences. It has made it possible to create more precise cellular and animal models, which has increased understanding of the genetics underlying human disease. Its potential is outstanding in a wide range of domains, including biomedical research, applied biotechnology, and basic research.
The most common tools for gene editing up until 2013 were engineered nucleases, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). However, the rate of advancement in the sector was constrained by their relatively low editing efficiency and lengthy development timeframes.[1]
The science of genome editing was revolutionized in 2013 with the discovery of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-associated nucleases, which are derived from a bacterial adaptive immunological defense mechanism. Short guide RNA (sgRNA) is used by the CRISPR/Cas9 system to control Cas9-mediated cleavage and donor HDR template insertion. A new era of genomic engineering has been brought about by the ease of use, adaptability, and high degree of adjustable nature of RNA design to retarget Cas9. This approach offers notable advantages over ZFNs and TALENS. In order to improve efficiency and lessen off-target effects, base and prime editing, as well as modified or alternative CRISPR nucleases (such as Cas12 and dead Cas9), are being researched in the fast developing field of gene editing.[2]
When comparing the off target effect is seen lower in ZFN, TALEN and high in CRISPR/CAS this becomes challenge in utilizing rather less time consuming gene editing technique and reason behind this is the target site of action which is DNA in case of CRISPR/CAS they can sometimes localize to unintended sites with sequence similarity to the on-target site. When a CRISPR-Cas system localizes to unintended sites and performs its programmed function there, this is an off-target effect. The off-target effects occur when Cas9 acts on untargeted genomic sites and creates cleavages that may lead to adverse outcomes.[3]
Treatment for cancer has been transformed by the gene engineering of T cells to create novel cancer immunotherapies such chimeric antigen receptor (CAR)-T cell therapy. While the clinical success rate of current autologous CAR-T immunotherapies is excellent, improvements in safety and efficacy characteristics are required. The goals of next-generation CAR-T designs are to produce universal CAR-T cells from allogeneic donors, increase CAR-T cell potency, reduce off-target effects, and expand the therapeutic targets beyond liquid cancers. These new tactics necessitate more intricate CRISPR/Cas9-enabled genetic engineering techniques, in which the efficiency, safety, and scalability of gene editing are greatly influenced by the gene delivery strategy selected.[4]
Genome editing technologies enable scientists to make changes to DNA, leading to changes in physical traits, like eye color, and disease risk. The first genome editing technologies were developed in the late 1900s. More recently, a new genome editing tool called CRISPR, invented in 2009, has made it easier than ever to edit DNA. CRISPR is simpler, faster, cheaper, and more accurate than older genome editing methods. Genome editing is of great interest in the prevention and treatment of human diseases. Genome editing is used in cells and animal models in research labs to understand diseases. Scientists are still working to determine whether this approach is safe and effective for use in people. It is being explored in research and clinical trials for a wide variety of diseases, including single-gene disorders such as cystic fibrosis, hemophilia, and sickle cell disease. It also holds promise for the treatment and prevention of more complex diseases, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infect...
(All Rights Reserved)